Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistanceJulie Strizki, Nicholas Murgolo, John M. Gaspar et al.|Antimicrobial Agents and Chemotherapy|2023Cited by 33
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT TrialJulie Strizki, Carisa De Anda, Arthur Fridman et al.|Infectious Diseases and Therapy|2023Cited by 11
543. Molnupiravir Maintains Antiviral Activity Against SARS-CoV-2 Variants In Vitro and in Early Clinical StudiesJay A. Grobler, Julie Strizki, Nicholas Murgolo et al.|Open Forum Infectious Diseases|2021Cited by 10
153. Molnupiravir Exhibits a High Barrier to the Development of SARS-CoV-2 Resistance in vitroJulie Strizki, Jay A. Grobler, Nicholas Murgolo et al.|Open Forum Infectious Diseases|2022Cited by 3
511. Treatment with Molnupiravir in the MOVe-In and MOVe-Out Clinical Trials Results in an Increase in Transition Mutations Across the SARS-CoV-2 GenomeJulie Strizki, Nicholas Murgolo, Ying Zhang et al.|Open Forum Infectious Diseases|2021Cited by 1